In Q3 2026, several pivotal biotech catalysts are poised to significantly influence the market landscape. There are 24 upcoming drug approvals on the FDA calendar, covering a range of indications and phases. Understanding these catalysts is crucial for investors aiming to make informed decisions and seize potential opportunities.

The full Q3 2026 biotech catalyst calendar

Ameluz®PDT: A Shift for Superficial Basal Cell Carcinoma

Ameluz®PDT, from Biofrontera Inc. (BFRI), stands out as a top-tier photodynamic therapy for superficial basal cell carcinoma (sBCC). This treatment uses 10% aminolevulinic acid (ALA) gel with red-light illumination to target sBCC lesions while sparing healthy tissue. The FDA aims to decide on the supplemental New Drug Application (sNDA) by September 28, 2026, with an 89% Probability of Approval (PoA). This high probability reflects strong clinical data, including a 65.5% clearance rate in key trials, compared to 4.8% for placebo (p<0.0001). The global market for sBCC treatment is about $1.2 billion, highlighting significant commercial potential for Ameluz. Despite a favorable safety profile with low pain scores and good cosmetic outcomes, investors should be aware of risks like reliance on the BF-RhodoLED® device and competition from non-surgical therapies.

Zervimesine: A Potential Breakthrough for Dementia with Lewy Bodies Psychosis

Zervimesine (CT1812), from Cognition Therapeutics (CGTX), is in Phase 2 trials for dementia with Lewy bodies (DLB) psychosis. The drug's Probability of Approval (PoA) is 23%, based on early Phase 2 SHIMMER study signals. This study, involving 130 participants, showed a good safety profile with a low 4.5% discontinuation rate at the 100 mg dose. The global DLB treatment market is estimated at $8.5 billion, as there are no FDA-approved therapies for this condition. The FDA has outlined a registrational path for DLB psychosis, but the absence of regulatory designations complicates progress. Investors should watch for FDA meeting minutes and the Phase 3 trial design announcement, which could greatly affect Zervimesine’s approval chances.

CT-95: New Ground in Solid Tumor Treatment

CT-95 (MSLN x CD3), from Context Therapeutics (CNTX), is in Phase 1a trials for solid tumors with a 19% Probability of Approval (PoA). This first-in-human, first-in-class T cell engager bispecific antibody targets MSLN-expressing tumors like pancreatic and ovarian cancers. The market for these tumors is about $15 billion, but the drug faces significant risks due to its early development stage and lack of efficacy data. Key upcoming events include initial data releases in mid-2026, crucial for investors. The absence of regulatory designations also raises concerns about market entry. Despite challenges, CT-95 could meet a significant need in oncology, making it a noteworthy investment opportunity.

ONS-5010/LYTENAVA™: Advancing Treatment for Neovascular AMD

Outlook Therapeutics (OTLK) is developing ONS-5010/LYTENAVA™ (bevacizumab-vikg) for neovascular age-related macular degeneration (nAMD). With a 65% Probability of Approval (PoA), this formulation offers an FDA-approved alternative to off-label repackaged products. The wet AMD market is projected to reach $15 billion, driven by the disease's high prevalence. The PDUFA date is December 31, 2025, and the safety profile aligns with bevacizumab's historical data. Challenges include mixed efficacy results from the NORSE trials. Risks involve potential FDA demands for more confirmatory evidence, which could delay commercialization. Investors should keep an eye on the FDA decision and any communications clarifying the required evidence.

NMRA-215: Exploring Preclinical Paths for Obesity

NMRA-215, an oral NLRP3 inhibitor from Neumora Therapeutics, targets obesity and is in preclinical development. The Probability of Approval (PoA) is just 4%, reflecting preclinical assets' challenges in a crowded field. Neumora plans to start clinical trials in Q1 2026, with 12-week human proof-of-concept data expected later that year. Although preclinical studies show promising weight loss, translating these to human efficacy is uncertain. The obesity market is projected to reach $33.5 billion globally by 2030, highlighting unmet needs despite existing therapies. Investors should consider the inherent risks, including the lack of human data and competition from established therapies.

Upcoming Catalysts: Key Events for Investors

Several critical catalysts are approaching as we move through 2026. Notable FDA PDUFA dates for Ameluz®PDT and ONS-5010 are set for September 28, 2026, and December 31, 2025, respectively. Zervimesine's upcoming Phase 3 trial design announcement will be pivotal for its future. Investors should also track NMRA-215's trial initiation and proof-of-concept data release later in the year. The overall landscape presents a mix of high potential and considerable risk, making these catalysts crucial for informed investment strategies.

The bottom line

Q3 2026 presents a mix of promising biotech catalysts and inherent risks. Investors should closely monitor these developments as they unfold.